



2023 Evidence to Implementation Award
Reviewer Scoring Tool

Applicant: _____ Reviewer: _____

Reminder: Scores should be whole numbers, not decimals

	Beginning 0	Developing 1-2	Accomplished 3-4	Exemplary 5-6	Score
1. Features & Benefits	The solution does not have advantages over current practice, and scientific justification is lacking.	The solution meets the performance of current deployed solutions at a competitive cost.	<p>The solution has measurable benefits over current deployed solutions, or offers substantive advantages in a market niche.</p> <p>The science behind the innovation is sound, the product has been developed, and tested with, at minimum, excellent pilot data.</p>	<p>There are substantial advantages to the product or service over current deployed solutions, or there is no one yet offering a comparable solution.</p> <p>The science behind the innovation is sound. The innovation/product /service is finished, the product has been satisfactorily tested.</p>	



	Beginning 0	Developing 1-2	Accomplished 3-4	Exemplary 5-6	Score
2. Demand/ Adoption/ Adopter Customers	At present, there is no independent market validation of the product, no adopter or first customers have agreed to test or purchase it, and/or does not meet a priority need based on reviewer experience.	Meets a priority need based on reviewer understanding of the healthcare system.	Market research has confirmed a specific market for the product or service, but to-date no commitments have been made to test or purchase the product.	Customers have been intimately involved in the development process and have committed to either purchase or try the product/service as soon as it becomes available.	
3. Competition/ Barriers to Entry	The product or service has significant existing competition that delivers equal or superior results.	The product or service is innovative, but there are limited formal mechanisms to reduce the likelihood that competitors will replicate key features in the future.	There is a level of unique knowledge or know-how deployed in the product or service, which might be patentable, or there is another unique property that makes it challenging but not impossible for others to replicate.	The product or service has received a patent or embeds proprietary technology or knowledge that is not easily replicated. Alternatively, the innovation has a unique feature (such as a brand) that creates a significant barrier to competitors.	
4. Potential for Impact	The innovation is estimated to have a low impact, and it is very unlikely to reach the target audience.	The innovation is estimated to have a modest impact, and reach a modest proportion of the target audience.	The innovation is estimated to have a moderate impact, and reach a moderate proportion of the target audience.	The innovation is impactful and a high enough proportion of the target audience can be reached to substantially impact their health; or substantially improve health care system processes.	



	Beginning 0	Developing 1-2	Accomplished 3-4	Exemplary 5-6	Score
5. Sustainability: Dissemination & Implementation Partners and Purveyors	No dissemination & implementation partners (purveyors) or supply chain partners have been identified.	At this point, although identified, no distribution or dissemination partners have yet been approached.	Possible dissemination partners have been identified and initial discussions held. While interested, there are no formal agreements in place with these partners.	Critical dissemination partners have been engaged in the development process, and have made firm commitments to participate as soon as the innovation or service is ready to scale-up.	
6. Sustainability: Financial Expectations	No confidence that a sustainable business model can be developed to pay for sustainable spread of the innovation.	Limited confidence that a sustainable business model can be developed to pay for sustainable spread of the program.	Reasonable degree of confidence that a sustainable business model can be developed.	High degree of confidence a sustainable business model can be developed.	
7a. Readiness: Innovation/ Product/ Service	Product is not well described.	The concept of the innovation has been established, but it still needs to be developed and tested.	The innovation has gone through different stages of product development. Dissemination and implementation packages still need to be tested for effectiveness.	The innovation/product /service is finished, the product has been tested, the implementation package has been shown to be effective, a dissemination plan has been developed.	



	Beginning 0	Developing 1-2	Accomplished 3-4	Exemplary 5-6	Score
7b. Readiness: Investigator and Team	Experience and commitment to implementation is not evident.	The PI and/or team members' experience is primarily technical, or limited, and provides no direct evidence that it will help them to support implementation and dissemination of their innovation. The PI lacks commitment and/or capacity to assist with dissemination, including hand-off to purveyor.	The PI and/or team member's significant skillsets and experience, which although not directly relevant, will help support their success. The PI is only moderately committed to seeing the process through to dissemination and hand-off to a purveyor, or there are some capacity challenges to the PI and team to assist with dissemination.	The PI and/or team members have deep and significant relevant experience that will support their success, and are highly committed to seeing the process through to dissemination including handing-off the intervention to a purveyor, and have the capacity to assist with dissemination.	
8. Health Equity: People/ Intended Customers	NONE of the data on health outcomes are described according to an underrepresented population that experiences disparities in the aspect of health that the innovation addresses.	LIMITED data on health outcomes are described according to an underrepresented population that experiences disparities in the aspect of health that the innovation addresses.	SOME data on health outcomes are described according to an underrepresented population that experiences disparities in the aspect of health that the innovation addresses.	ALL data on health outcomes are described according to one or more underrepresented populations that experience disparities in the aspect of health that the innovation addresses.	
9. Health Equity: Partners/ Purveyors	NO dissemination & implementation partners (purveyors) or supply chain partners who work with the intended underrepresented populations have been identified	At this point, although identified , no distribution or dissemination partners who work with the intended underrepresented populations have yet been approached	Possible dissemination partners who work with the intended underrepresented populations have been identified and initial discussions held . While interested, there are no formal agreements in place with these partners	Critical dissemination partners who work with the intended underrepresented populations have been engaged in the development process, and have made firm commitments to participate as soon as the innovation or service is ready to scale-up.	



	Beginning 0	Developing 1-2	Accomplished 3-4	Exemplary 5-6	Score
10. Health Equity: Approach	The intervention and its implementation strategies have <u>NOT</u> been adapted for the intended audience AND There is no evidence of effectiveness or feasibility in this underrepresented population	The project seeks to accomplish ONE of the following: <ul style="list-style-type: none">• The intervention(s) <u>and/or</u> the implementation strategies will be adapted for the intended audience.• There is evidence that this approach is either effective or feasible in this underrepresented population.	The intervention <u>and</u> its implementation strategies are appropriate for the intended audience AND There is evidence that this approach is either effective or feasible in this underrepresented population.	The intervention and its implementation strategies are appropriate for the intended audience AND There is evidence that the intervention is effective and feasible to implement in this underrepresented population.	

11. Overall Rating

Provide a rating between 0-6 to indicate the likelihood for a project to have long-term success with scale-up combined with the likelihood for scale-up to reduce health disparities, based on the 10 above criteria

12. Comments: (Provide bullet points)

Strengths:

-
-
-
-

Weaknesses:

-
-
-
-